8-K: KORU Medical Systems Announces CEO Transition

KORU Medical Systems announces CEO Linda Tharby's retirement and the appointment of Adam Kalbermatten as her successor, effective July 1, 2026, with a structured transition plan.

Summary

• Linda Tharby will retire as President and Chief Executive Officer of KORU Medical Systems, Inc. effective June 30, 2026.
• Ms. Tharby will continue to serve as a non-executive advisory employee and on the Board through December 31, 2026, to facilitate an orderly transition.
• Adam Kalbermatten has been appointed President effective March 15, 2026, and will succeed Ms. Tharby as Chief Executive Officer effective July 1, 2026.
• Mr. Kalbermatten's annual base salary will be $450,000 through June 30, 2026, increasing to $525,000 effective July 1, 2026.
• Mr. Kalbermatten is eligible for a pro-rated 2026 annual bonus with a 50% target for January 1-March 15, 2026, and an 80% target for March 16-December 31, 2026, payable 70% cash and 30% fully vested RSUs.
• Mr. Kalbermatten will receive a 2025 long-term incentive award valued at $550,000 (33% stock options, 33% RSUs, 33% PSUs) and a 2026 target LTI award of $1,250,000 (50% PSUs, 25% RSUs, 25% stock options).
• A one-time Promotion PSU award with a grant value of $1,250,000 will be granted to Mr. Kalbermatten effective July 1, 2026, vesting based on multi-year revenue growth (75%) and market capitalization (25%) objectives.
• Ms. Tharby's compensation includes regular base salary through June 30, 2026, a 100% payout for her 2025 bonus, and a prorated 2026 bonus; during her advisory period, she will receive 50% of her prior base salary.
• Ms. Tharby will retain 100% of 2024 LTIP PSUs and 50% of 2025 LTIP PSUs, subject to performance, and specific tranches of 2024 and 2025 RSUs and options will vest in 2027 and 2028.
• 220,000 Sales Growth PSUs granted to Ms. Tharby were earned and vested based on certified 2025 performance, while 200,000 PSUs were previously cancelled, and remaining unvested PSUs are forfeited.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The orderly transition and clear incentive structure for the new CEO suggest stability and a forward-looking approach, which can be reassuring to investors, despite the inherent uncertainty of a leadership change.

Positives

• The company has established a clear and orderly leadership transition plan, ensuring continuity in executive roles.
• The incoming CEO, Adam Kalbermatten, has a well-defined compensation structure, including significant long-term incentive awards tied to performance, aligning his interests with shareholders.
• Linda Tharby's continued advisory role and Board service through December 31, 2026, provides valuable support during the transition period.
• The compensation package for the outgoing CEO includes provisions for earned bonuses and extended vesting for certain equity awards, reflecting a mutually agreed-upon separation.

Negatives

• Linda Tharby will forfeit a significant portion of her unvested equity awards, including remaining Sales Growth PSUs and Market Capitalization PSUs if unvested after April 12, 2026.
• The company will incur costs associated with both the outgoing and incoming CEO's compensation during the transition period, including severance-like benefits for Ms. Tharby and a new compensation package for Mr. Kalbermatten.

Risks

• Leadership transitions, even when planned, can introduce uncertainty regarding future strategic direction and operational execution.
• The performance-based equity awards for the new CEO, Adam Kalbermatten, are subject to achieving multi-year revenue growth and market capitalization objectives, which carry inherent market and operational risks.
• The company's ability to retain key talent during and after the CEO transition period could be a challenge.
• Potential for disruption to investor and analyst relationships during the formal handoff process by the outgoing CEO.

Future Outlook

The company anticipates a smooth leadership transition with Adam Kalbermatten assuming the CEO role, supported by a comprehensive compensation package designed to incentivize multi-year performance in revenue growth and market capitalization. The structured handover with Linda Tharby's advisory role aims to maintain strategic continuity and investor relations through the end of 2026. The new CEO's long-term incentive targets signal a focus on sustained growth and shareholder value creation.

Management Comments

• Linda Tharby will continue to serve as a non-executive advisory employee following her retirement through December 31, 2026, to facilitate an orderly transition.
• The transition agreement and employment agreement are mutually negotiated arrangements intended to promote continuity and retain cooperation during the leadership change.
• All transition-related communications will reflect a constructive and collaborative leadership transition.

Industry Context

StockSavvy.ai notes that orderly CEO transitions are crucial in the medical device industry, where long-term strategic vision, regulatory navigation, and product innovation are paramount. A well-managed succession, as outlined by KORU Medical Systems, can mitigate investor uncertainty often associated with leadership changes. The emphasis on revenue growth and market capitalization in the new CEO's incentive structure aligns with broader industry trends focusing on scaling operations and enhancing shareholder value in a competitive landscape.

Comparison to Industry Standards

• Adam Kalbermatten's initial base salary of $450,000, increasing to $525,000, and a target LTI of $1,250,000 for 2026, are competitive for a CEO of a publicly traded medical device company of KORU Medical Systems' size, comparable to packages seen at emerging growth companies in the med-tech sector.
• The mix of PSUs, RSUs, and stock options in the LTI awards, with a significant portion tied to performance metrics like revenue growth and market capitalization, is a standard practice in the industry to align executive incentives with long-term shareholder value, similar to structures at companies like Inari Medical or Shockwave Medical at similar stages of growth.
• The severance package, including 12 months of base salary and health benefits, is a common provision for executive employment agreements in the U.S. market, providing a safety net for executives in the event of a termination without cause or for good reason.
• Linda Tharby's advisory role and extended equity vesting for specific tranches during the transition period are indicative of a carefully managed succession, often employed to ensure knowledge transfer and minimize disruption, a practice observed in transitions at companies like Zimmer Biomet or Stryker when senior leaders depart.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from a clear succession plan, potentially reducing uncertainty. The new CEO's performance-based incentives align with shareholder value creation. However, a change in leadership always carries some level of risk regarding future strategic direction.
• Employees: Will experience a change in top leadership, which can impact company culture and strategic priorities. The structured transition aims to minimize disruption.
• Customers and Suppliers: The orderly transition and continued advisory role of the outgoing CEO are intended to ensure continuity in relationships and operations, minimizing potential negative impacts.
• Creditors: The stability provided by a planned leadership transition generally maintains confidence in the company's management and financial health.

Next Steps

• Adam Kalbermatten will officially assume the role of President on March 15, 2026.
• Adam Kalbermatten will officially assume the role of Chief Executive Officer on July 1, 2026.
• Linda Tharby will continue to serve as a non-executive advisory employee and on the Board through December 31, 2026.
• The Board is expected to appoint Adam Kalbermatten to the Board of Directors effective January 1, 2027.
• Adam Kalbermatten's 2026 long-term incentive award is anticipated to be granted in March/April 2027.

Key Dates

Recommendation

The filing details a well-structured and orderly CEO transition, which is a positive for corporate governance and stability. However, a change in top leadership, even when planned, introduces a period of uncertainty as the new CEO establishes their strategic vision and operational priorities. While the compensation package for the incoming CEO is robust and performance-aligned, investors will likely await initial strategic announcements and early performance indicators under the new leadership before making significant investment decisions. Therefore, a 'hold' recommendation is appropriate to observe the execution of the new leadership's strategy.

Keywords

KORU Medical Systems, KRMD, CEO transition, executive compensation, corporate governance, leadership change, medical devices, retirement, employment agreement, equity awards